189 related articles for article (PubMed ID: 7518859)
1. Clinical modulation of multidrug resistance in multiple myeloma: effect of cyclosporine on resistant tumor cells.
Sonneveld P; Schoester M; de Leeuw K
J Clin Oncol; 1994 Aug; 12(8):1584-91. PubMed ID: 7518859
[TBL] [Abstract][Full Text] [Related]
2. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study.
Sonneveld P; Marie JP; Huisman C; Vekhoff A; Schoester M; Faussat AM; van Kapel J; Groenewegen A; Charnick S; Zittoun R; Löwenberg B
Leukemia; 1996 Nov; 10(11):1741-50. PubMed ID: 8892677
[TBL] [Abstract][Full Text] [Related]
3. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.
Dalton WS; Grogan TM; Meltzer PS; Scheper RJ; Durie BG; Taylor CW; Miller TP; Salmon SE
J Clin Oncol; 1989 Apr; 7(4):415-24. PubMed ID: 2564428
[TBL] [Abstract][Full Text] [Related]
4. Atypical multi-drug resistance (MDR): low sensitivity of a P-glycoprotein-expressing human T lymphoblastoid MDR cell line to classical P-glycoprotein-directed resistance-modulating agents.
Jachez B; Loor F
Anticancer Drugs; 1993 Dec; 4(6):605-15. PubMed ID: 7905300
[TBL] [Abstract][Full Text] [Related]
5. Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON.
Sonneveld P; Durie BG; Lokhorst HM; Marie JP; Solbu G; Suciu S; Zittoun R; Löwenberg B; Nooter K
Lancet; 1992 Aug; 340(8814):255-9. PubMed ID: 1353189
[TBL] [Abstract][Full Text] [Related]
6. SDZ PSC-833--a novel potent in vitro chemosensitizer in multiple myeloma.
Jonsson B; Nilsson K; Nygren P; Larsson R
Anticancer Drugs; 1992 Dec; 3(6):641-6. PubMed ID: 1363199
[TBL] [Abstract][Full Text] [Related]
7. MDR-1 expression and response to vincristine, doxorubicin, and dexamethasone chemotherapy in multiple myeloma refractory to alkylating agents.
Cornelissen JJ; Sonneveld P; Schoester M; Raaijmakers HG; Nieuwenhuis HK; Dekker AW; Lokhorst HM
J Clin Oncol; 1994 Jan; 12(1):115-9. PubMed ID: 7903690
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of P-glycoprotein-mediated vinblastine transport across HCT-8 intestinal carcinoma monolayers by verapamil, cyclosporine A and SDZ PSC 833 in dependence on extracellular pH.
Zacherl J; Hamilton G; Thalhammer T; Riegler M; Cosentini EP; Ellinger A; Bischof G; Schweitzer M; Teleky B; Koperna T
Cancer Chemother Pharmacol; 1994; 34(2):125-32. PubMed ID: 7910786
[TBL] [Abstract][Full Text] [Related]
9. Effects of amiodarone, cyclosporin A, and PSC 833 on the cytotoxicity of mitoxantrone, doxorubicin, and vincristine in non-P-glycoprotein human small cell lung cancer cell lines.
van der Graaf WT; de Vries EG; Timmer-Bosscha H; Meersma GJ; Mesander G; Vellenga E; Mulder NH
Cancer Res; 1994 Oct; 54(20):5368-73. PubMed ID: 7923167
[TBL] [Abstract][Full Text] [Related]
10. Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914).
Sonneveld P; Suciu S; Weijermans P; Beksac M; Neuwirtova R; Solbu G; Lokhorst H; van der Lelie J; Dohner H; Gerhartz H; Segeren CM; Willemze R; Lowenberg B; ; ;
Br J Haematol; 2001 Dec; 115(4):895-902. PubMed ID: 11843823
[TBL] [Abstract][Full Text] [Related]
11. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy.
Grogan TM; Spier CM; Salmon SE; Matzner M; Rybski J; Weinstein RS; Scheper RJ; Dalton WS
Blood; 1993 Jan; 81(2):490-5. PubMed ID: 8093668
[TBL] [Abstract][Full Text] [Related]
12. P-glycoprotein expression and activity of resistance modifying agents in primary cultures of human renal and adrenocortical carcinoma cells.
Fridborg H; Larsson R; Juhlin C; Rastad J; Akerström G; Backlin K; Nygren P
Anticancer Res; 1994; 14(3A):1009-16. PubMed ID: 7915506
[TBL] [Abstract][Full Text] [Related]
13. Circulating monoclonal B cells expressing P glycoprotein may be a reservoir of multidrug-resistant disease in multiple myeloma.
Pilarski LM; Belch AR
Blood; 1994 Feb; 83(3):724-36. PubMed ID: 7507731
[TBL] [Abstract][Full Text] [Related]
14. VAD-cyclosporine therapy for VAD-resistant multiple myeloma.
Weber D; Dimopoulos M; Sinicrope F; Alexanian R
Leuk Lymphoma; 1995 Sep; 19(1-2):159-63. PubMed ID: 8574163
[TBL] [Abstract][Full Text] [Related]
15. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
[TBL] [Abstract][Full Text] [Related]
16. Microfluorometric evaluation of calcein acetoxymethyl ester as a probe for P-glycoprotein-mediated resistance: effects of cyclosporin A and its nonimmunosuppressive analogue SDZ PSC 833.
Liminga G; Nygren P; Larsson R
Exp Cell Res; 1994 Jun; 212(2):291-6. PubMed ID: 7910563
[TBL] [Abstract][Full Text] [Related]
17. Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer.
Salmon SE; Dalton WS; Grogan TM; Plezia P; Lehnert M; Roe DJ; Miller TP
Blood; 1991 Jul; 78(1):44-50. PubMed ID: 1676918
[TBL] [Abstract][Full Text] [Related]
18. Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group.
Friedenberg WR; Rue M; Blood EA; Dalton WS; Shustik C; Larson RA; Sonneveld P; Greipp PR
Cancer; 2006 Feb; 106(4):830-8. PubMed ID: 16419071
[TBL] [Abstract][Full Text] [Related]
19. Modulator activity of PSC 833 and cyclosporin-A in vincristine and doxorubicin-selected multidrug resistant murine leukemic cells.
Lopes EC; Scolnik M; Alvarez E; Hajos SE
Leuk Res; 2001 Jan; 25(1):85-93. PubMed ID: 11137565
[TBL] [Abstract][Full Text] [Related]
20. The maturation of myeloma cells correlates with sensitivity to chemotherapeutic agents.
Kuroda Y; Sakai A; Okikawa Y; Munemasa S; Katayama Y; Hyodo H; Imagawa J; Takimoto Y; Okita H; Ohtaki M; Kimura A
Int J Hematol; 2005 May; 81(4):335-41. PubMed ID: 15914366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
